| P50 | author | Thomas Moreau | Q80282050 |
| | Jacques A Nunes | Q58937410 |
| P2093 | author name string | C Tonnelle | |
| | C Chabannon | |
| | B Calmels | |
| | F Bardin | |
| | V Barlogis | |
| P2860 | cites work | A tissue-specific MAR/SAR DNA-binding protein with unusual binding site recognition | Q24321970 |
| | Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice | Q24669724 |
| | Gene transfer in humans using a conditionally replicating lentiviral vector | Q24675343 |
| | Gene therapy for severe combined immunodeficiency: are we there yet? | Q24680426 |
| | Distinct genomic integration of MLV and SIV vectors in primate hematopoietic stem and progenitor cells | Q24796392 |
| | Tec kinases: a family with multiple roles in immunity | Q28143522 |
| | Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy | Q28215190 |
| | Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration | Q28242708 |
| | Bruton's tyrosine kinase is not essential for LPS-induced activation of human monocytes | Q62640362 |
| | Colocalization of X-linked agammaglobulinemia and X-linked immunodeficiency genes | Q72835320 |
| | Enhanced transgene expression in cord blood CD34(+)-derived hematopoietic cells, including developing T cells and NOD/SCID mouse repopulating cells, following transduction with modified trip lentiviral vectors | Q73800420 |
| | The health status and quality of life of adults with X-linked agammaglobulinemia | Q82080189 |
| | The Ser36-Ser37 Pair in HeLa Nuclear Protein p21/SIIR Mediates Ser/Thr Phosphorylation and Is Essential for Rous Sarcoma Virus Long Terminal Repeat Repression | Q28291766 |
| | Ex vivo generation of fully mature human red blood cells from hematopoietic stem cells | Q28300052 |
| | Rac2 stimulates Akt activation affecting BAD/Bcl-XL expression while mediating survival and actin function in primary mast cells | Q28586410 |
| | The immunoglobulin heavy-chain matrix-associating regions are bound by Bright: a B cell-specific trans-activator that describes a new DNA-binding protein family | Q28590045 |
| | In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector | Q29547503 |
| | Transcription start regions in the human genome are favored targets for MLV integration | Q29618456 |
| | Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia | Q30195143 |
| | Development of a self-inactivating lentivirus vector. | Q33784841 |
| | Btk/Tec kinases regulate sustained increases in intracellular Ca2+ following B-cell receptor activation | Q33888592 |
| | The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases | Q34355151 |
| | Bruton's tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling. | Q34386319 |
| | Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. | Q34508425 |
| | Advances in lentiviral vector design for gene-modification of hematopoietic stem cells. | Q35012889 |
| | Stable transduction of quiescent CD34(+)CD38(-) human hematopoietic cells by HIV-1-based lentiviral vectors | Q35064224 |
| | Lentivirus vectors incorporating the immunoglobulin heavy chain enhancer and matrix attachment regions provide position-independent expression in B lymphocytes | Q35149980 |
| | Bruton tyrosine kinase is tyrosine phosphorylated and activated in pre-B lymphocytes and receptor-ligated B cells | Q35864977 |
| | Correction of the X-linked immunodeficiency phenotype by transgenic expression of human Bruton tyrosine kinase under the control of the class II major histocompatibility complex Ea locus control region | Q35957766 |
| | Genetic analysis of patients with defects in early B-cell development | Q36015046 |
| | HIV, but not murine leukemia virus, vectors mediate high efficiency gene transfer into freshly isolated G0/G1 human hematopoietic stem cells | Q36326611 |
| | Integrated self-inactivating lentiviral vectors produce full-length genomic transcripts competent for encapsidation and integration | Q36684330 |
| | Appearance of human plasma cells following differentiation of human B cells in NOD/SCID mouse spleen | Q36792950 |
| | Potential application of gene therapy to X-linked agammaglobulinemia. | Q36985468 |
| | Transduction of nondividing cells using pseudotyped defective high-titer HIV type 1 particles | Q37090592 |
| | Expression of the (recombinant) endogenous immunoglobulin heavy-chain locus requires the intronic matrix attachment regions | Q38502702 |
| | Extension of chromatin accessibility by nuclear matrix attachment regions. | Q38502889 |
| | Mutually exclusive interaction of a novel matrix attachment region binding protein and the NF-muNR enhancer repressor. Implications for regulation of immunoglobulin heavy chain expression | Q38505126 |
| | Dependence of enhancer-mediated transcription of the immunoglobulin mu gene on nuclear matrix attachment regions | Q38506663 |
| | Cell-specific and efficient expression in mouse and human B cells by a novel hybrid immunoglobulin promoter in a lentiviral vector. | Q40081805 |
| | Restriction of transgene expression to the B-lymphoid progeny of human lentivirally transduced CD34+ cells. | Q40539299 |
| | Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice | Q41541610 |
| | Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning | Q44044895 |
| | B-cell-specific transgene expression using a self-inactivating retroviral vector with human CD19 promoter and viral post-transcriptional regulatory element | Q44296349 |
| | Sustained correction of B-cell development and function in a murine model of X-linked agammaglobulinemia (XLA) using retroviral-mediated gene transfer | Q45875318 |
| | Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector | Q45880148 |
| | A phase I/II clinical trial of beta-globin gene therapy for beta-thalassemia | Q45889126 |
| | A developmental-specific factor binds to suppressor sites flanking the immunoglobulin heavy-chain enhancer. | Q52245349 |
| | X-Linked Agammaglobulinemia | Q62111760 |
| P433 | issue | 12 | |
| P921 | main subject | gene therapy | Q213901 |
| P304 | page(s) | 942-952 | |
| P577 | publication date | 2008-03-06 | |
| P1433 | published in | Gene Therapy | Q15763095 |
| P1476 | title | Development of an enhanced B-specific lentiviral vector expressing BTK: a tool for gene therapy of XLA | |
| P478 | volume | 15 | |